16:04 , Jul 11, 2018 |  BC Innovations  |  Translation in Brief

Poisoning the stromal chalice

A study published in the Journal of Clinical Investigation suggests antibody-drug conjugates targeting the tumor stroma could treat cancers by co-opting a stromal mechanism to feed cytotoxic drugs to the surrounding tumor cells. Tumor-associated stroma, which...
22:51 , Jun 28, 2018 |  BC Innovations  |  Translation in Brief

Conformist nanobodies

A University of Zurich team in collaboration with Roche has figured out how to make fully synthetic nanobodies that can bind to membrane proteins in specific conformations -- simultaneously opening up new target space for...
15:27 , Jun 8, 2018 |  BC Week In Review  |  Company News

Opthotech gains gene therapy for ophran vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and the University of Pennsylvania. The deal gives the biotech an adeno-associated virus...
20:58 , Jun 7, 2018 |  BC Extra  |  Company News

Ophthotech gains gene therapy for orphan vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) gained $0.29 (10%) to $3.09 on Thursday on news that it acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and...
01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing fibroblast...
16:23 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

Biogen Inc. (NASDAQ:BIIB) discontinued development of natalizumab to treat acute ischemic stroke after the drug missed the primary and secondary endpoints in the Phase IIb ACTION 2 trial in the indication. Biogen markets natalizumab, a humanized...
20:34 , Feb 7, 2018 |  BC Extra  |  Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

Biogen Inc. (NASDAQ:BIIB) discontinued development of natalizumab to treat acute ischemic stroke after the drug missed the primary and secondary endpoints in the Phase IIb ACTION 2 trial in the indication. Biogen markets natalizumab, a humanized...
01:12 , Feb 2, 2018 |  BC Innovations  |  Translation in Brief

Untangling MS

Multiple sclerosis researchers have typically sought to dial down inflammation and reduce disease metrics that encompass a wide range of disabilities. A UCLA team is bucking those trends by identifying disease-modifying targets in specific brain...
16:47 , Feb 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest agonizing ABCA1 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, a tool compound ABCA1 agonist increased walking ability and rotarod...